Zydus Cadila gets tentative USFDA nod for cocktail drug Emtricitabine, Tenofovir Disoproxil Fumarate to treat HIV
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: TRuvADA Tablets).
Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are used with other HIV medications to help control HIV infection.
This product is a combination of two different drugs: Emtricitabine and Tenofovir Disoproxil Fumarate and helps to decrease the amount of HIV in the body so that the immune system can work better.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.